The DOI matches its OpenAlex record; 1 of the 1 references it cites were found in a registry or an index.
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis
Open accessAbstract
Evidence suggests IgE may play a role in chronic rhinosinusitis (CRS). We sought to determine if treatment with a monoclonal antibody against IgE (omalizumab) is effective in reducing CRS inflammation. We performed a randomized, double blind, placebo controlled clinical trial in subjects with CRS despite treatment (including surgery). Subjects were randomized to receive omalizumab or placebo for 6 months. The primary outcome was quantitative measurement of sinus inflammation on imaging. Secondary outcome measures included quality of life, symptoms, and cellular inflammation, nasal airflow (NPIF) and olfactory testing (UPSIT). Subjects on omalizumab showed reduced inflammation on imaging after treatment, whereas those on placebo showed no change. The net difference, however, was not different between treatments. Treatment with omalizumab was associated with improvement in the Sino-Nasal Outcome Test (SNOT-20) at 3, 5, and 6 months compared to baseline with no significant changes in the control group. Remaining measures showed no significant differences across treatments. We conclude that IgE plays, at most, a small role in the mucosal inflammation of CRS and the symptoms. Placebo controlled, blinded studies with larger enrollment are needed to determine the clinical significance of any potential change.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rhinosinusitis in severe asthma
Bresciani, M., Paradis, L., Des Roches, A., Vernhet, H., Vachier, I., Godard, P., Bousquet, J., & Chanez, P. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.111593 · Cited by 345
Cited by
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
Self-citationInternational Consensus Statement on Allergy and Rhinology: Rhinosinusitis
Orlandi, R. R., Kingdom, T. T., Hwang, P. H., Smith, T. L., Alt, J. A., Baroody, F. M., Batra, P. S., Bernal‐Sprekelsen, M., Bhattacharyya, N., Chandra, R. K., et al. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21695 · Cited by 892
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Executive Summary of EPOS 2020 Including Integrated Care Pathways
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., & Mullol, J. (2020) · Rhinology journal · doi:10.4193/rhin20.601 · Cited by 533
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
Bachert, C., Zhang, L., & Gevaert, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.010 · Cited by 317
Metadata
- Authors
- Pinto, J. M., Mehta, N., DiTineo, M., Wang, J., Baroody, F. M., & Naclerio, R. M.
- Venue
- Rhinology Journal
- Publisher
- European Rhinologic Society
- Published
- 2010-09-01
- Volume
- 48
- Issue
- 3
- Pages
- 318-324
- ISSN
- 0300-0729 (ISSN-L)
- OpenAlex
- W31716537
- Cited by
- 238
- References
- 1
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.